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BACKGROUND: Although the efficacy of plerixafor in
peripheral blood stem cell (PBSC) mobilization has
been explored in several studies, factors associated
with successful plerixafor mobilization after administra-
tion of granulocyte–colony-stimulating factor (G-CSF),
with or without chemotherapy, have not been investi-
gated. We analyzed data on PBSC mobilization from a
large Italian database of lymphoma and myeloma
plerixafor-treated patients.
STUDY DESIGN AND METHODS: Two endpoints were
established to define successful mobilization: patients
with at least 2 ¥ 106 CD34+ cells/kg collected by three
leukapheresis procedures and patients achieving a
peak count of at least 20 ¥ 106 CD34+ cells/L during
mobilization.
RESULTS: Plerixafor achieved successful mobilization
in both predicted (n = 64) and proven poor mobilizers
(PMs; n = 143), classified according to the Gruppo Ital-
iano Trapianto di Midollo Osseo (GITMO) criteria. Suc-
cessful mobilization was independent of type of
mobilization (steady state or chemotherapy); age; sex;
disease; number or type of chemotherapy regimens
preceding plerixafor; radiation therapy; prior treatment
with melphalan, carmustine, lenalidomide, and radioim-
mune conjugates; and laboratory variables. Multivariate
analysis identified previous fludarabine treatment and
premobilization platelet count as predictors of success-
ful mobilization.
CONCLUSION: This large, prospective, nationwide
study confirmed plerixafor efficacy for mobilizing PBSCs
when added to G-CSF with or without chemotherapy.
Plerixafor can overcome negative effects of most pre-
dictors of poor mobilization to achieve satisfactory
harvest both in predicted and proven PM.
H
igh-dose chemotherapy followed by autolo-
gous stem cell transplantation (ASCT) is a
standard therapeutic approach for patients
with non-Hodgkin’s lymphoma (NHL),
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ROC = receiver operating characteristic.
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Hodgkin’s lymphoma (HL), or multiple myeloma (MM).1
The preferred source of hematopoietic stem cells for ASCT
is represented by peripheral blood stem cells (PBSCs),
since they are easier to collect and engraft faster than
marrow-derived cells.2,3
Historically, granulocyte–colony-stimulating factor
(G-CSF) or granulocyte macrophage-CSF, with or without
chemotherapy, have been used to mobilize stem cells.
However, these strategies do not always result in success-
ful mobilization.3-6 A recent survey involving 1040 patients
with NHL, HL, or MM, shows that a relevant proportion of
patients (6%-27%) failed to mobilize a sufficient number
of CD34+ progenitor cells for ASCT regardless of whether
G-CSF was used alone or with chemotherapy.5 Notewor-
thy, factors predicting successful PBSC mobilization in
patients with hematologic malignancies are still poorly
investigated,7-10 although their identification would
improve collection efficiency and prevent unnecessary
apheresis procedures, thus allowing a patient-tailored
mobilization and collection strategy.11
Plerixafor (Mozobil, Genzyme BV, Naarden, Nether-
lands, Sanofi licencing distribution in Italy) is a novel
CXCR4 chemokine receptor antagonist used in PBSC
mobilization.12 The interaction of the CXCR4 receptor with
the chemokine (C-X-C motif) ligand 12 (CXCL12) plays a
pivotal role in retaining CD34+ cells in the marrow
niches.12 Therefore, the blockade of this interaction leads
to the mobilization of stem cells into peripheral blood
(PB).12 The efficacy of plerixafor in the mobilization of
PBSCs is supported by the results of two randomized,
double-blind, multicenter trials in adult patients with
NHL or MM.13,14 Moreover, the results of compassionate-
use studies conducted in patients with lymphoma or MM
demonstrated that plerixafor plus G-CSF successfully and
safely induces stem cell mobilization in the majority of
patients who had previously failed a mobilization attempt
(i.e., collected CD34+ cells did not reach the minimum
number to proceed to ASCT or patients did not undergo
apheresis because of low PB CD34+ cell count) or patients
who were predicted to be poor mobilizers (PMs; e.g.,
heavily treated patients).15-20 Although the efficacy of
plerixafor in PBSC mobilization has been explored in
several studies, to our knowledge the factors potentially
associated with successful mobilization after the admin-
istration of this agent have not been specifically investi-
gated. To this end, this study analyzes a large Italian
database of patients treated with plerixafor.
PATIENTS AND METHODS
Study setting and design
This multicenter, prospective, observational cohort study
was conducted in 23 Italian centers with experience in the
treatment of hematologic malignancies and performance
of stem cell mobilization and ASCT between January 2010
and December 2011. The study was conducted in accor-
dance with the Declaration of Helsinki, and the ethical
committee of each center approved the study protocol. All
patients signed an informed and educated consent before
their inclusion in the study.
Patients and interventions
Patients with NHL, HL, or MM requiring PBSC mobiliza-
tion were screened for inclusion in this study. Mobiliza-
tion was performed using G-CSF, with or without
chemotherapy, depending on individual center policy.
G-CSF was given at a dosage of 10 mg/kg when used alone
and 5 mg/kg when administered after chemotherapy.
Plerixafor was given at a dosage of 240 mcg/kg body
weight. (Sanofi licencing distribution in Italy)
Patients were categorized as proven or predicted PMs,
according to the Gruppo Italiano Trapianto di Midollo
Osseo (GITMO) criteria.21 Patients were considered to be
“proven PMs” when the peak concentration of PB CD34+
cells, after adequate mobilization, was fewer than 20 ¥ 106
cells/L or if the concentration of CD34+ cells collected
with up to three apheresis procedures was not more than
2.0 ¥ 106 CD34+ cells/kg and considered to be “predicted
PMs” if they had failed a previous collection attempt (not
otherwise specified), previously received extensive radio-
therapy or full courses of therapy affecting stem cell mobi-
lization, and met two of the following criteria: advanced
disease (at least two lines of chemotherapy), refractory
disease, extensive marrow involvement or cellularity less
than 30% at the time of mobilization, or age at least
65 years.21
Data storage
Data were collected in a centralized secured database and
were analyzed at the end of the study. The database con-
sisted of three different parts: 1) demographic character-
istics and previous history of mobilization; 2) type of
mobilization; and 3) posttransplantation follow-up.
Endpoints and data analysis
Two endpoints were established to evaluate mobilization
success: 1) at least 2 ¥ 106 CD34+ cells/kg body weight
collected with up to three leukapheresis procedures and 2)
a peak count of at least 20 ¥ 106/L CD34+ cells ¥ 106/L PB
during mobilization.21
The fold increase of CD34+ cells ¥ 106/L after the
administration of plerixafor was also calculated, to deter-
mine the increase of PB CD34+ progenitor cells before and
after the administration of plerixafor. The correlation
between the platelet (PLT) concentration and the end-
points were investigated using receiver operating charac-
teristic (ROC) curves. A ROC curve permits a comparison
of two operating characteristics or variables as the values
change to enable thresholds to be established—in this
case comparing endpoints with other variables, to better
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differentiate patients likely to reach the endpoints (i.e.,
achieve successful mobilization) from those not reaching
the endpoints.22
Patients were stratified according to several variables:
age; sex; “predicted” versus “proven” PM category; chemo-
therapy versus steady-state mobilization strategy; diagno-
sis (NHL, HL, MM); the number of chemotherapy
regimens preceding plerixafor administration; use of flu-
darabine, radiation therapy, melphalan, carmustine, lena-
lidomide, and radioimmune conjugates; and laboratory
variables (hemoglobin, PLT count, white blood cells
[WBCs], and neutrophils). Each variable was tested using
univariate statistical analysis, to establish whether it could
discriminate patients reaching the endpoint from those
not reaching the endpoint, thus becoming a possible sig-
nificant predictor of mobilization after plerixafor therapy.
The chi-square test or Fisher’s exact test was used for cat-
egorical variables, according to the number of samples.
For continuous normally distributed variables, the t test
was applied, whereas the Wilcoxon test was used for non-
normally distributed variables. The two endpoints were
analyzed separately and p values of less than 0.05 were
considered significant.
To identify the factors able to predict the outcome of
plerixafor treatment, a multivariate logistic regression
model was calculated using only the variables that were
significant in the univariate analysis as covariates. Covari-
ates were considered to significantly affect the prediction
if the p value was less than 0.05.
Finally, Kaplan-Meier curves were drawn to evaluate
the relationship between the number of plerixafor doses
and the endpoints. All the analyses were conducted on the
population as a whole and on the subpopulations of pre-
dicted PMs and proven PMs.
RESULTS
Baseline characteristics
The baseline characteristics of the study patients are
shown in Table 1. In total, 218 patients were enrolled (114
males; 52%). The mean age was 55.6  11.6 years (range,
17-76 years). Approximately half of the patients (n = 108;
49.5%) were affected by NHL; 23 patients (10.6%) had HL
and 84 (38.5%) had MM. Three patients were diagnosed
with other hematologic diseases (one subject with plasma
cell leukemia, one with Richter syndrome, and one with
immune thrombocytopenia purpura) and were not
included in the subsequent analysis; therefore, 215
patients with NHL (n = 108), HL (n = 23), or MM (n = 84)
requiring mobilization of PBSCs were included in the
study. Concerning the mobilization status (predicted PM
vs. proven PM) before plerixafor administration, data were
available for 207 patients: among these, 64 (30.9%) were
predicted PMs and 143 (69.1%) were proven PMs.
In total, 86 patients received G-CSF after chemo-
therapy, according to different schedules (for six patients
data unknown): 40 patients (50%) received high-dose
cyclophosphamide ( 3 g/m2); 14 patients (17.5%) were
treated with DHAP (dexamethasone, ARA-C, cisplatin)
regimen; five patients (6.3%) with etoposide (1 g/m2,
Vepesid, Bristol-Myers Squibb, Rome, Italy); seven
patients (8.8%) with cytarabine (3 g/m2, Aracytin,
Janssen-Cilag, Berchem, Belgium); three patients (3.8%)
with a mitoxantrone, cytarabine, and dexamethasone
(MAD) regimen and 10 patients (12.5%) with other regi-
mens. In the 126 remaining patients, PBSC mobilization
was based on G-CSF (10 mg/kg) in combination with
plerixafor (240 mg/kg body weight) without chemo-
therapy (steady state).
Efficacy of plerixafor
Overall, more than the 60% of patients enrolled in the
study reached the endpoints, measured either as the
number of CD34+ cells/kg collected (145 patients, 68.1%)
or as the peak value of circulating CD34+ cells ¥ 106/L (118
patients, 60.8%; Table 2). In total, 61 patients (35.5%)
reached the endpoint of at least 2 ¥ 106 CD34+/kg with
one apheresis procedure, and 80 (46.5%) with two apher-
esis procedures, so that more than 80% of patients
(n = 141) reached the target with no more than two aph-
eresis procedures.
The high response rate was observed after both
steady state (G-CSF) and chemomobilization (Table 2).
However, in NHL patients, chemomobilization was
TABLE 1. Baseline demographics and clinical
characteristics in the total population
Variable Subgroup Total




Diagnosis and mobilization strategy
MM 84 (38.5)†
Chemotherapy 46 (58.0)
Steady state 33 (42.0)
NHL 108 (49.5)
Chemotherapy 53 (56.0)
Steady state 41 (44.0)
HL 23 (10.6)
Chemotherapy 17 (77.0)
Steady state 5 (23.0)
Other 3 (1.4)
Mobilization category‡ 207
Predicted PM 64 (30.9)
Proven PM 143 (69.1)
Mobilization strategy 212
Chemotherapy 86 (40.6)
Steady state 126 (59.4)
* Data are reported as mean  SD (range) or number (%).
† Note that not all details were available for all patients. Per-
centages are given accordingly.
‡ According to GITMO criteria.21
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associated with a higher proportion of patients reaching
the end points compared with patients mobilized with
plerixafor plus G-CSF alone (64% vs. 39% for the propor-
tion of patients with peak CD34+ during mobilization of at
least 20 ¥ 106/L CD34+ cells ¥ 106/L and 71% vs. 55% for
the number of CD34+ cells/kg collected 2 ¥ 106 CD34+
cells/kg with up to three leukapheresis procedures),
although these differences did not reach significance.
Patients with MM showed the highest response rate
with 82.5% of patients with more than 2 ¥ 106 CD34+
cells/kg collected in up to three apheresis procedures and
75.3% patients with a peak value of more than 20 ¥ 106
CD34+ cells/L, compared to other patients (p = 0.0016,
Table 3).
Overall, the data showed a fivefold increase of
PB CD34+ cells ¥ 106/L after plerixafor administration
(Fig. 1). The fold increase was higher for NHL patients (6.8
times) and lower for HL patients (3.3 times) and there was
no difference in fold increase between predicted PM and
proven PM (Fig. 1).
At the time of data analysis, of 126 (57.0%) patients
receiving ASCT, 118 cases (95%) engrafted. Six patients did
not engraft due to early death after auto-ASCT. A
transplant-related mortality of 5% (six patients) was
observed. Analysis of the cumulative percentage of
patients reaching the endpoints (Fig. 2) showed that
almost 90% reached the defined study endpoints after
three doses of plerixafor.
Predictive factors for mobilization success
Statistical analysis showed that baseline PLT concentra-
tion was the most powerful predicting factor for successful
stem cell mobilization (Table 3). The ROC curve estima-
tion provided significant discrimination thresholds of
140 ¥ 109/L to reach more than 2 ¥ 106 CD34+ cells/kg and
143 ¥ 109/L to reach more than 20 ¥ 106 CD34+ cells/L.
Lack of radiotherapy was also a significant predictor of
successful stem cell mobilization (Table 3). The only other
factor predicting poor mobilization in the overall popula-
tion was the previous use of fludarabine. In particular,
patients previously treated with fludarabine were signifi-
cantly less capable of reaching the endpoints (20% vs.
60%; p = 0.0009 in the univariate analysis). In the multi-
variate analysis, these three variables, but not type of
disease, still kept a significant predictive capacity for suc-
cessful mobilization.
Overall similar observations came from the analysis
of predicted PM (Table 4) and proven PM (Table 5): PLT
concentration was the only factor with a discriminant
capability. As in the total population, the estimation of the
ROC curve for PLT concentration provided a threshold for
TABLE 2. Diagnosis and mobilization characteristics by endpoint (CD34+ cells/kg or peak
CD34+ cells ¥ 106/L status)
Patient characteristics






(<20 ¥ 106 cells/L)
Mobilizer
(>20 ¥ 106 cells/L)
<0.5 0.5-1 1-2 2-5 >5 <10 10-20 <20
Total population 46 (21.6) 6 (2.8) 16 (7.5) 84 (39.4) 61 (28.7) 38 (19.6) 38 (19.6) 118 (60.8)
Diagnosis
NHL 29 (27.1) 5 (4.7) 11 (10.3) 62 (57.9) 28 (29.8) 19 (20.2) 47 (50)
HL 6 (26.1) 0 (0.0) 1 (4.3) 16 (69.6) 4 (20.0) 5 (25.0) 11 (55)
MM 10 (12.4) 1 (1.3) 3 (3.8) 19 (23.8) 47 (58.7)† 6 (7.8) 13 (16.9) 58 (75.3)
Mobilization category‡
Predicted PM 14 (22.0) 49 (78.0) 18 (34) 35 (66)
Proven PM 49 (35.0) 90 (65.0) 58 (42) 80 (58)
Mobilization strategy
Chemotherapy 37 (32.0) 80 (68.0) 49 (44) 62 (56)
Steady state 21 (26.0) 59 (74.0) 23 (31) 52 (69)
Diagnosis and mobilization strategy
NHL
Chemotherapy 12 (29.0) 29 (71.0) 14 (36) 25 (64)
Steady state 24 (45.0) 29 (55.0) 30 (61) 19 (39)
HL
Chemotherapy 2 (40.0) 3 (60.0) 1 (33) 2 (67)
Steady state 4 (24.0) 13 (76.0) 7 (44) 9 (56)
MM
Chemotherapy 7 (21.0) 26 (79.0) 8 (25) 24 (75)
Steady state 7 (16.0) 38 (84.0) 11 (25) 33 (75)
* Data are reported as number (%).
† At least 4 ¥ 106 CD34+ cells/kg (cut off for MM patients).
‡ According to GITMO criteria.21
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discriminating patients likely to reach the endpoints from
those not likely to reach the endpoints. Notably, when
examining the univariate analysis of the predicted PMs,
patients who did not receive fludarabine had a higher
probability of reaching the endpoints
(80% vs. 20% for >2 ¥ 106 CD34+ cells/kg
and 75% vs. 0% for >20 ¥ 106 CD34+
cells/L; p < 0.05 [Table 4]), whereas this
factor was not significant in the proven
population in the univariate analysis
(Table 5).
For CD34+ cells ¥ 106/L, the predic-
tive multivariate model was calculated
only for the proven PM population,
because the low number of cases in the
predicted poor population did not allow
a reliable estimation.
When we analyzed the number of
CD34+ cells collected/kg in different
patient subpopulations, the only factor
with a predictive capability, both in the
univariate and in the multivariate
model, was the PLT concentration. This
finding was present in all patient
categories.
The statistical analysis also showed a correlation
between the peak of CD34 cells ¥ 106/L and the harvest of
CD34 cells/kg in patients treated with plerixafor (Spear-
man coefficient, 0.78704; p < 0.0001). ROC curve analysis
TABLE 3. Significant predictive factors in the total population





CD34+ cells/kg Diagnosis NHL 45 (42.1) 62 (57.9) 0.0016 NS
HL 7 (30.4) 16 (69.6)
MM 14 (17.5) 66 (82.5)
Mobilization status Predicted 14 (22.0) 49 (78.0) NS Not considered
Proven 49 (35.0) 90 (65.0)
Mobilization strategy Chemotherapy 37 (32.0) 80 (68.0) NS Not considered
Steady state 21 (26.0) 59 (74.0)
PLTs (¥109/L) Number 59 140 <0.0001 <0.0001
Mean  SD 116.48  69.83 176.52  89.33
100 22 (49) 23 (51) 0.0013 <0.0001
>100 37 (24) 117 (76)
140* 38 (44) 49 (56) 0.0001 <0.0001
>140* 21 (19) 91 (81)
Radiotherapy No 46 (27) 122 (73) 0.028 0.044
Yes 15 (47) 17 (53)
CD34+ cells ¥ 106/L Diagnosis NHL 47 (50) 47 (50) NS NS
HL 9 (45) 11 (55)
MM 19 (25) 58 (75)
Mobilization category† Predicted 18 (34) 35 (66) NS Not considered
Proven 58 (42) 80 (58)
Mobilization strategy Chemotherapy 49 (44) 62 (56) NS Not considered
Steady state 23 (31) 52 (69)
PLTs (¥109/L) Number 71 117 <0.0001 <0.0001
Mean  SD 122.56  67.54 178.32  89.50
100 26 (60) 17 (40) 0.0005 0.0004
>100 45 (31) 100 (69)
143* 46 (54) 39 (46) <0.0001 0.0002
>143* 25 (24) 78 (76)
Fludarabine No 63 (36) 111 (64) 0.0009 0.0175
Yes 12 (80) 3 (20)
* Cutoff obtained by ROC curve analysis.
† According to GITMO criteria.21
Fig. 1. Fold increase in CD34+ cells ¥ 106/L after plerixafor treatment in predicted
and proven PMs and in the total population.
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further permitted the estimation of a significant discrimi-
nation threshold of 4 mL of CD34+ cells for a successful
mobilization with plerixafor.
DISCUSSION
The results presented here confirmed, on a large database
including more than 200 patients from several Italian
centers, the efficacy of plerixafor in inducing stem cell
mobilization and, for the first time, identified factors
predictive of successful mobilization after the administra-
tion of this novel agent. Our results are in agreement
with those obtained in randomized, Phase III and
compassionate-use program trials,8-10,13-20,23 in which the
administration of plerixafor produced a successful mobi-
lization with a median increase of approximately fivefold
in patients with MM and NHL. We found no significant
difference between the response of patients who were pre-
dicted PMs or proven PMs. Moreover, we did not observe
any difference between steady state and chemotherapy
mobilization, thus suggesting that plerixafor can be incor-
porated successfully into both regimens.
Preliminary studies in patients previously failing the
first mobilization attempt reported a successful rate
ranging from 37% to 90%.15,17,18 Our results on a larger
Italian database were similar, with more than 60% of
the total population reaching the endpoints. Our results
also confirm that rates of successful mobilization tend
to be lower in patients with NHL than in patients with
MM or HL.9 In addition, in our study, approximately
90% of patients reaching the endpoint needed no
more than three doses of plerixafor and two apheresis
procedures.
Moreover, a high correlation
between increased likelihood of mobili-
zation success and increased number
of CD34+ cells present in the mobilized
blood was documented; a cutoff point of
4 ¥ 106 CD34+/L cells best predicted
success in a plerixafor-containing
mobilization regimen. Based on this, it
can be postulated that the presence of at
least 4 ¥ 106 CD34+/L cells in the mobi-
lized blood, prior plerixafor administra-
tion, identified patients who most
benefited from plerixafor usage in all
patient categories.
In our population the analysis of
factors potentially able to influence the
treatment outcome was different from
those reported in previous studies.8,18
We failed to demonstrate that patients
who underwent previous ASCT had a
lower median number of CD34+ cells
collected than those who did not
undergo ASCT. Moreover, previous chemotherapy was
not a significant factor discriminating patients reaching
the endpoint from those not reaching the endpoint,
neither in the total population nor in the two subgroups
(predicted vs. proven), except for the use of fludarabine.
In fact, in our population only 20% of the patients who
were treated with fludarabine achieved the endpoint of
at least 20 ¥ 106 CD34+/L, compared to the 64% of those
who did not receive fludarabine. This difference was
greater than reported in the literature (60% vs. 76%).10
The subanalysis by proven or predicted PMs showed that
this effect was only seen in patients who were predicted
PMs (using both endpoints).
Our analysis also allowed the definition of a baseline
PLT concentration threshold that may be used as a predic-
tive factor for successful mobilization with plerixafor. In
fact, baseline thrombocytopenia was a significant predic-
tor of reduced mobilization success, although plerixafor
treatment was able to overcome this effect partially.
Overall, a PLT count of fewer than 150 ¥ 109/L was signifi-
cantly associated with a lower probability of successful
mobilization regardless of the endpoint considered or in
all subgroups of patients.
In conclusion, our study shows that the admini-
stration of plerixafor produced a successful mobilization
in lymphoma and myeloma patients, both in predicted
and in proven PMs, independent of the type of
mobilization (steady state or chemotherapy). We also
identified some factors, including baseline PLT concen-
tration, previous fludarabine treatment, and previous
radiotherapy, which, in a multivariate model, may
be able to predict the successful mobilization with
plerixafor.
Fig. 2. Cumulative percentage of patients reaching the efficacy endpoints in relation
to the number of plerixafor doses. ( ) At least 20 ¥ 106 CD34+/L; ( ) at least
2 ¥ 106 CD34+/kg.
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TABLE 4. Significant predictive factors in the predicted PM population (n = 64)
Endpoint Factor Categories Nonmobilizer Mobilizer
p value
Univariate Multivariate
CD34+ cells/kg Diagnosis NHL 10 (33) 20 (67) NS NS
HL 1 (13) 7 (87)
MM 3 (12) 22 (88)
Mobilization strategy Chemotherapy 5 (14) 30 (86) NS Not considered
Steady state 9 (32) 19 (68)
PLTs (¥109/L) N 14 47 0.0052 0.043
Mean  SD 101.71  77.98 193.38  109.88
100 7 (50) 7 (50) 0.011 NS
>100 7 (15) 40 (85)
103* 9 (53) 8 (47) 0.0005 0.027
>103* 5 (11) 39 (89)
Fludarabine No 10 (18) 47 (82) 0.0014 NS
Yes 4 (80) 1 (20)
WBCs N 14 47 0.0199 NS
Median 6.14 15.36
CD34+ cells ¥ 106/L Diagnosis NHL 11 (44) 14 (56) NS Not estimated
HL 2 (40) 3 (60)
MM 5 (22) 18 (78)
Mobilization strategy Chemotherapy 10 (33) 20 (67) NS
Steady state 8 (35) 15 (65)
PLTs (¥109/L) Number 17 34 0.046
Mean  SD 126.18  82.17 189.76  113.53
100 6 (50) 6 (50) NS
>100 11 (28) 28 (72)
143* 11 (55) 9 (45) 0.0084
>143* 6 (19) 25 (81)
Fludarabine No 13 (28) 34 (72) 0.0033
Yes 5 (100) 0 (0)
WBCs Number 17 34 0.0021
Median 4.70 22.68
Neutrophil count (¥109/L) Number 17 29 0.012
Median 3.24 8.5
* Cutoff obtained by ROC curve analysis.
TABLE 5. Significant predictive factors in the proven PM population (n = 144)
Endpoint Factor Categories Nonmobilizer Mobilizer p value univariate p value multivariate
CD34+ cells/kg Diagnosis NHL 30 (43) 39 (57) 0.034 NS
HL 6 (40) 9 (60)
MM 11 (21) 41 (79)
Mobilization type Chemotherapy 32 (40) 50 (61) NS Not considered
Steady state 12 (25) 37 (75)
PLTs (¥109/L) Number 45 90 0.001 0.0017
Mean  SD 121.07  67.37 163.61  70.05
100 15 (48) 16 (52) 0.043 0.027
>100 30 (29) 74 (71)
129* 24 (46) 28 (54) 0.012 0.0069
>129* 21 (25) 62 (75)
Sex Male 21 (27) 56 (73) 0.028 NS
Female 28 (45) 34 (55)
CD34+ cells ¥ 106/L Diagnosis NHL 36 (53) 32 (47) NS NS
HL 7 (47) 8 (53)
MM 14 (27) 38 (73)
Mobilization type Chemotherapy 39 (48) 42 (52) NS 0.0166
Steady state 15 (31) 34 (69)
PLTs (¥109/L) N 54 80 0.0001 <0.0001
Mean  SD 121.42  63.09 168.91  71.60
100 20 (65) 11 (35) 0.0017 0.0003
>100 34 (33) 69 (67)
142* 35 (54) 30 (46) 0.0019 0.0013
>142* 19 (27) 50 (73)
* Cutoff obtained by ROC curve analysis.
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